High-risk HPV testing has proven utility in both cervical cancer screening and management. The 2012 screening guidelines endorsed by the ACS, ASCCP, and the American Society for Clinical Pathology state that combined cervical cytology and HPV testing is now the preferred strategy for women aged 30 years. The 2012 ASCCP guidelines for the management of abnormal cervical cancer screening tests and cancer precursors utilize cotesting extensively as both a sensitive and efficient way to manage and follow these women. Inappropriate or too-frequent screening, including HPV testing, can lead to increased costs without proven benefit, and may also cause patient harm by overtreatment. The educational statement below is intended to improve adherence to current guidelines, thereby improving the health care of women. The American College of Obstetricians and Gynecologists affirms these recommendations and the US Preventive Services Task Force states that cotesting is acceptable. 6, 7 1. High-risk (oncogenic) HPV DNA testing is appropriate in the following circumstances:
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1.1. Routine cervical cancer screening in conjunction with cervical cytology (cotesting) for women aged 30 to 65 years (for women aged 30 years-65 years with cytology reported as absent or insufficient endocervical/transformation zone component, early repeat cytology is not indicated and cotesting is preferred). 1.1.1. For women whose cytology and HPV results are both negative, repeat both tests only after a 5-year interval (applies only to routine screening; for women with negative cotests after previous abnormal cytology, see below). The intent of this summary is to facilitate provider education and to encourage the appropriate utilization of HPV testing. Clinical judgment should always be used when applying a guideline to an individual patient because it is impossible to develop guidelines that will apply to all situations.
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